The critique discusses 58 peptides in different clinical phases, indicating a sturdy pipeline of peptide therapies focusing on PPIs. These approaches open new avenues for treatment plans customized to fight specific breast cancer subtypes and glioblastoma by honing in on integrins, fibronectins, and matrix metalloproteinases. These studies in